PCN75 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab versus Ibrutinib in High-Risk Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Unified Health System (SUS)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.167
https://www.valueinhealthjournal.com/article/S1098-3015(21)00384-3/fulltext
Title :
PCN75 Cost-Minimization and Budget Impact Analysis of Venetoclax plus Obinutuzumab versus Ibrutinib in High-Risk Patients with Untreated Chronic Lymphocytic Leukemia in the Brazilian Unified Health System (SUS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00384-3&doi=10.1016/j.jval.2021.04.167
First page :
Section Title :
Open access? :
No
Section Order :
10749